Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S, Wang J, Cheng Y, Mok T, Chang J, Zhang L, Feng J, Tu HY, Wu L, Zhang Y, Luft A, Zhou JY, Ma Z, Lu Y, Hu C, Shi Y, Ying K, Zhong H, Poddubskaya E, Soo RA, Chia YH, Li A, Li A, Wu YL.
Lu S, et al. Among authors: chang j.
Lung Cancer. 2021 Feb;152:7-14. doi: 10.1016/j.lungcan.2020.11.013. Epub 2020 Nov 24.
Lung Cancer. 2021.
PMID: 33321441
Free article.
Clinical Trial.